Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness
暂无分享,去创建一个
David Tweats | Marcel Kaiser | M. A. Bray | Els Torreele | Michael A. Bray | R. Brun | M. Kaiser | Reto Brun | E. Torreele | D. Tweats | B. Pécoul | Bernadette Bourdin Trunz | Guy Mazué | Bernard Pécoul | G. Mazué | Bernadette Bourdin Trunz
[1] M. Boelaert,et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. , 2008, Emerging infectious diseases.
[2] D. Murphy. Safety pharmacology of the respiratory system: Techniques and study design , 1994 .
[3] F. Chappuis,et al. Human African Trypanosomiasis in Areas without Surveillance , 2010, Emerging infectious diseases.
[4] J. Frearson,et al. HTS and hit finding in academia – from chemical genomics to drug discovery , 2009, Drug discovery today.
[5] J. Périé,et al. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. , 1995, Acta tropica.
[6] R Fautz,et al. In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. , 2007, Mutagenesis.
[7] P. Kennedy,et al. Human African trypanosomiasis of the CNS: current issues and challenges. , 2004, The Journal of clinical investigation.
[8] C. Barry,et al. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. , 2004, Current pharmaceutical design.
[9] W. Raether,et al. Chemotherapeutically active nitro compounds. 4.5-Nitroimidazoles (Part II). , 1978, Arzneimittel-Forschung.
[10] T. Baltz,et al. Cultivation in a semi‐defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. , 1985, The EMBO journal.
[11] Jimmy Opigo,et al. NECT trial: more than a small victory over sleeping sickness , 2009, The Lancet.
[12] Nihal Ahmad,et al. Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] R. Kaminsky,et al. Melarsoprol refractory T. b. gambiense from Omugo, north‐western Uganda , 2001, Tropical medicine & international health : TM & IH.
[14] F. Nesslany,et al. In vitro and in vivo chromosomal aberrations induced by megazol. , 2004, Mutation research.
[15] B. Ames,et al. Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.
[16] S. Irwin,et al. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.
[17] D. Boykin,et al. New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289 , 2009, Antimicrobial Agents and Chemotherapy.
[18] The effect of reducing the number of cells scored on the performance of the in vivo rat liver UDS assay. , 1995, Mutation research.
[19] F. Jennings,et al. The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronicT. brucei infections in mice , 2004, Zeitschrift für Parasitenkunde.
[20] A. Basu,et al. Mutagenicity of nitroaromatic compounds. , 2000, Chemical research in toxicology.
[21] G. Duménil,et al. Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS Chromotest , 1992, Environmental and molecular mutagenesis.
[22] Salah Ghabri,et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.
[23] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[24] R. Brun,et al. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis. , 2008, Acta tropica.
[25] Anika Ashok,et al. ICH Harmonised Tripartite Guideline , 2009 .
[26] C. E. Voogd. On the mutagenicity of nitroimidazoles. , 1981, Mutation research.
[27] R. Kaminsky,et al. In Vitro and In Vivo Activities of Trybizine Hydrochloride against Various Pathogenic Trypanosome Species , 1998, Antimicrobial Agents and Chemotherapy.
[28] M. Matsumoto,et al. OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.
[29] Human African trypanosomiasis (sleeping sickness): epidemiological update. , 2006, Releve epidemiologique hebdomadaire.
[31] F. Chappuis,et al. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] M. Hayashi,et al. In vivo rodent micronucleus assay: protocol, conduct and data interpretation. , 2000, Mutation research.
[33] H. Rosenkranz,et al. Evidence for the existence of a family of bacterial nitroreductases capable of activating nitrated polycyclics to mutagens. , 1981, Environmental mutagenesis.
[34] D. Horn,et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences.
[35] P. Hoffmann,et al. Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. , 2002, Mutation research.
[36] M K Pugsley,et al. Principles of Safety Pharmacology , 2008, Handbook of Experimental Pharmacology.
[37] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[38] P. Simarro,et al. Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next> , 2008, PLoS medicine.
[39] K. Lamp,et al. Metronidazole. A therapeutic review and update. , 1997, Drugs.
[40] GUIDANCE DOCUMENT,et al. Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use , 2008 .
[41] M. Barrett,et al. Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease , 2007, British journal of pharmacology.
[42] M. Fenech. Cytokinesis-block micronucleus cytome assay , 2007, Nature Protocols.
[43] M. Barrett,et al. Activity of Megazol, a Trypanocidal Nitroimidazole, Is Associated with DNA Damage , 2003, Antimicrobial Agents and Chemotherapy.
[44] I. Hidalgo,et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.
[45] C Helma,et al. Predictive Models for Carcinogenicity and Mutagenicity: Frameworks, State-of-the-Art, and Perspectives , 2009, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.
[46] Michael Snowden,et al. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind". , 2008, Current opinion in drug discovery & development.
[47] Honglu Zhang,et al. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[48] Clifton E. Barry,et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.
[49] W. Raether,et al. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. , 1983, Annals of tropical medicine and parasitology.
[50] R. Kaminsky,et al. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.
[51] P. Wardman,et al. Reduction Potentials of One-Electron Couples Involving Free Radicals in Aqueous Solution , 1989 .
[52] C. Burri,et al. Treatment of human African trypanosomiasis--present situation and needs for research and development. , 2002, The Lancet. Infectious diseases.
[53] Pranav Shah,et al. Role of Caco‐2 Cell Monolayers in Prediction of Intestinal Drug Absorption , 2006, Biotechnology progress.